August 28, 2013
Otsuka Pharmaceutical Co., Ltd.
UCB Japan Co. Ltd.
Japan's First Dry Syrup Formulation of an Anti-epileptic Drug for the Treatment of Partial-onset Seizures, E Keppra® Dry Syrup 50%, to Be Launched on August 29
- E Keppra® Dry Syrup 50% (levetiracetam) is a sweet, powdered formulation that dissolves readily in water and can be easily ingested even by children. Its dosage can easily be adjusted to body weight of children. It also contributes to better compliance in adult patients including some elderly patients who experience difficulty in swallowing tablets. E Keppra® Dry Syrup 50% is Japan's first dry syrup formulation available for adjunctive treatment of partial-onset seizures.
- E Keppra® (brand name outside Japan: Keppra®) has been approved in over 100 countries and regions, including the US, as a new anti-epilepsy drug with a different mechanism of action from conventional drugs. In Japan, it was launched in 2010 as a new treatment option for patients whose seizures are not adequately controlled by existing treatments. E Keppra has subsequently attained a 25% share of the Japanese anticonvulsant market as a widely prescribed combination therapy.
- Epilepsy is a cranial nerve disease with a relatively high incidence、 affecting about 1 in 100 people. It occurs mainly in children and in the elderly. Continual administration of anti-epileptic drugs is critical since it is difficult to predict when seizures will occur. Through continual treatment with anti-epileptic drugs, over 70% of patients can lead seizure-free lives.
Otsuka Pharmaceutical Co., Ltd. (head office: Tokyo; President and Representative Director: Taro Iwamoto) and UCB Japan Co., Ltd. (head office: Tokyo; President and Representative Director: Joel Peterson) launched E Keppra® Dry Syrup 50% (generic name: levetiracetam; E Keppra Dry Syrup) on August 29.
Information in this news release was current as of the original release date.